AEON — Aeon Biopharma Share News
0.000.00%
Brief: Aeon Biopharma And Priveterra Announce Arrangement Of Up To $125 Million Of Financing
Brief: Priveterra Acquisition Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Priveterra Acquisition Special Meeting Adjourned To June 13
Brief: Priveterra Acquisition Corp Says On April 27, Co, Aeon And Priveterra Merger Sub Entered Into An Amendment No. 1 To Business Combination Agreement
Brief: Priveterra Acquisition Corp Previously Issued Consolidated Financial Statements As Of And For Year Ended Dec 31, 2022 Should No Longer Be Relied Upon
Brief: Priveterra Acquisition Corp And Aeon Biopharma Inc Enter Financing Agreements For $20 Mln
Brief: Aeon Biopharma And Priveterra Acquisition Corp Announce Additional Capital Commitment From Existing Investors For At Least $20 Mln
Brief: Aeon Biopharma, Priveterra Acquisition Corp Announce Filing Of S-4 Registration Statement For Proposed Business Combination
Brief: Aeon Biopharma Inc- Topline Data Expected To Be Announced In 2H 2023
Brief: Aeon Biopharma Completes Enrollment In Phase 2 Trial Of Abp-450 For Preventive Treatment Of Episodic Migraine
Brief: AEON Biopharma Merges With Priveterra Acquisition To Become Publicly Listed